Succinobucol—a well-studied antioxidant that prevents TF expression in monocytic cell lines [91]—has been tested in more than 6,000 patients with recent acute coronary syndromes and did not confer protective effects to justify its use therapeutically [141]. This evidence concerns the gene TF and acute coronary syndrome.